Product Description
Mechanisms of Action: ADORA Deamination,Deoxyadenosine Deamination
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Greece | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Leadiant Biosciences, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|